Humana expands value-based care with new cancer and kidney disease initiatives
Humana Inc., a leading health and well-being company, has reinforced its commitment to value-based care by introducing two major healthcare initiatives. The company has announced ... Read More
Gloriosa Superba: Chemical constituents, medicinal uses, and pharmaceutical importance
Gloriosa superba, commonly referred to as the glory lily, is a highly valued medicinal plant recognized for its potent chemical composition and extensive pharmaceutical applications. ... Read More
Bristol Myers Squibb’s Opdualag fails to meet primary endpoint in Phase 3 trial
Bristol Myers Squibb has announced that its Phase 3 RELATIVITY-098 clinical trial, designed to evaluate Opdualag (nivolumab and relatlimab-rmbw) for adjuvant melanoma treatment, failed to ... Read More
City of Hope researchers unveil thymus regeneration therapy for immune system repair
Scientists at City of Hope, one of the most renowned cancer research and treatment institutions in the United States, have uncovered a novel method to ... Read More
Dr Reddy’s launches toripalimab in India as first immuno-oncology drug for nasopharyngeal carcinoma
Dr. Reddy’s Laboratories Ltd. announced a significant milestone in its oncology portfolio with the launch of Toripalimab in India. This innovative immuno-oncology drug is the ... Read More
BeiGene stock surges on EU approval for TEVIMBRA in advanced cancer treatment
BeiGene, a global oncology company, announced that the European Commission has granted regulatory approval for TEVIMBRA (tislelizumab), its PD-1 monoclonal antibody, for the first-line treatment ... Read More
Game-changing cancer therapy: Imugene’s VAXINIA receives FDA orphan drug status for bile tract cancer
Imugene Limited has received a significant boost with the United States Food and Drug Administration (FDA) granting Orphan Drug Designation (ODD) to its experimental therapy, ... Read More
New data from Incyte highlights efficacy of CDK2 inhibitor in ovarian cancer; Pivotal trials expected in 2025
Incyte has announced new early-stage clinical data for INCB123667, a highly selective and potential first-in-class CDK2 inhibitor, showing promising results in patients with advanced solid ... Read More
Health Canada approves KEYTRUDA and Enfortumab Vedotin for advanced urothelial cancer
Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced that Health Canada has granted approval for KEYTRUDA (pembrolizumab) in combination ... Read More
Exscientia takes full ownership of cdk7 inhibitor in oncology breakthrough
Exscientia plc (Nasdaq: EXAI), a pioneer in AI-driven drug discovery, has reached a strategic milestone by acquiring full ownership of the oral CDK7 inhibitor program ... Read More